Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ICAD Inc ICAD

Healthcare Medical Devices
iCAD, Inc. provides artificial intelligence-powered cancer detection. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to better serve patients by... see more

Recent & Breaking News (NDAQ:ICAD)

New Research Confirms iCAD's ProFound AI Aids Breast Cancer Detection with Digital Breast Tomosynthesis, Improves Radiologists' Workflow

GlobeNewswire April 19, 2021

iCAD Announces Estimated Q1 Revenues and Upcoming CFO Transition

GlobeNewswire April 5, 2021

New Research Indicates ProFound AI May Reduce Interval Breast Cancer Rates

GlobeNewswire March 31, 2021

iCAD Announces FDA Clearance for ProFound AI Version 3.0 for 3D Mammography

GlobeNewswire March 15, 2021

New Research Supporting ProFound AI Presented at European Congress of Radiology Online Meeting

GlobeNewswire March 8, 2021

iCAD Announces Closing of $25.0 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire March 8, 2021

iCAD to Participate in the Cowen 41st Annual Health Care Conference

GlobeNewswire March 3, 2021

iCAD Announces Pricing of $22.0 Million Public Offering of Common Stock

GlobeNewswire March 3, 2021

iCAD Announces Proposed Public Offering of Common Stock

GlobeNewswire March 2, 2021

iCAD Reports Financial Results for Fourth Quarter and Year Ended December 31, 2020

GlobeNewswire February 24, 2021

iCAD to Report Fourth Quarter 2020 Financial Results on Wednesday, February 24

GlobeNewswire February 18, 2021

iCAD to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

GlobeNewswire February 16, 2021

iCAD to Participate in B. Riley Securities Virtual Oncology Investor Conference

GlobeNewswire January 19, 2021

iCAD to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event

GlobeNewswire January 6, 2021

iCAD Announces Renowned Neuro-Oncologist Santosh Kesari, MD, PhD to Lead Post-Market Study for Treatment of Recurrent Glioblastoma (GBM) with FDA-cleared Xoft Brain IORT Technology to Support Clinical Adoption

GlobeNewswire December 29, 2020

Solis Mammography Adopts iCAD's ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution

GlobeNewswire December 10, 2020

iCAD Hosting Investor Webinar on Expanded ProFound AI Portfolio with New Breast Cancer Risk Assessment Solution

GlobeNewswire December 3, 2020

iCAD Highlights Expanded Suite of Leading Breast Health AI Solutions at Virtual RSNA 2020

GlobeNewswire November 30, 2020

iCAD Announces Promising Clinical Data to be Presented on Treatment of Early-Stage Breast and Gynecological Cancers at ESTRO 2020 Online Congress

GlobeNewswire November 25, 2020

iCAD Reports Over 1,000 Licenses Sold as Part of ProFound AI Sales

GlobeNewswire November 24, 2020